30 November 2017 - ALK today announced that it has reached a satisfactory agreement with health authorities in France for the pricing and reimbursement of its house dust mite sublingual allergy immunotherapy tablet, Acarizax.

Acarizax in France is indicated for both allergic rhinitis and allergic asthma in house dust mite-allergic adult patients whose condition is not well controlled by symptom-relieving medications, and also for the treatment of adolescent patients with house dust mite-induced allergic rhinitis. 

A marketing authorisation for France was first granted in January 2016 and since then, ALK has been in dialogue with the authorities to secure market access for the product.

Read ALK Abello press release